Reduced expression or mutations in SOCS1 and SOCS3 have been associated with sustained STAT3 activation, accelerating the progression of pancreatic ductal adenocarcinoma [220], prostate cancer [221], and glioblastoma [222]. The gene discussed is STAT3; the disease is prostate cancer.